We are live on !
Find out more
Stempoint Capital Portfolio holdings
AUM
$581M
Turnover
56.9%
1-Year Est. Return
373.68%
This Fund
S&P 500
This Quarter Est. Return
-9.68%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$38.1M
(-10%)
Cap. Flow
+$15.6M
Cap. Flow % of AUM
Cap. Flow %
4.57%
Top 10 Holdings %
Top 10 Hldgs %
55.38%
Holding
79
New
17
Increased
14
Reduced
10
Closed
36
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunocore
IMCR
|
+$17.3M |
| 2 |
Immunovant
IMVT
|
+$10.9M |
| 3 |
Merck
MRK
|
+$10.5M |
| 4 |
GSK
GSK
|
+$10.3M |
| 5 |
Arcellx
ACLX
|
+$7.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$11.7M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$11.2M |
| 3 |
Roivant Sciences
ROIV
|
+$9.22M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$8.08M |
| 5 |
Insmed
INSM
|
+$7.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.45% |
| 2 | Financials | 0.44% |
| 3 | Miscellaneous | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Syndax Pharmaceuticals
SNDX
$854M
| $29M | 8.52% |
1,412,176
+311,188
| +28% | +$6.51M |
2023 Q4
2 quarters
|
|
|
2
Roivant Sciences
ROIV
$29.8B
| $28.7M | 8.43% |
2,712,741
-841,103
| -24% | -$9.22M |
2023 Q4
2 quarters
|
|
|
3
Immunovant
IMVT
$7.39B
| $26.7M | 7.85% |
1,011,879
+384,651
| +61% | +$10.9M |
2023 Q4
2 quarters
|
|
4
DELISTED
Crinetics Pharmaceuticals
CRNX
| $24.7M | 7.25% |
551,095
-68,694
| -11% | -$3.17M |
2023 Q4
2 quarters
|
|
5
DELISTED
Merus
MRUS
| $17.1M | 5.02% |
288,668
+54,797
| +23% | +$2.65M |
2023 Q4
2 quarters
|
|
|
6
DELISTED
Arcellx
ACLX
| $15.5M | 4.55% |
280,709
+140,442
| +100% | +$7.63M |
2023 Q4
2 quarters
|
|
7
DELISTED
Amicus Therapeutics
FOLD
| $14.8M | 4.36% |
1,495,047
-52,094
| -3% | -$535K |
2023 Q4
2 quarters
|
|
|
8
Immunocore
IMCR
$1.67B
| $11.5M | 3.38% |
+339,351
| New | +$17.3M |
2024 Q2
0 quarters
|
|
9
DELISTED
Applied Therapeutics
APLT
| $10.3M | 3.03% |
2,211,320
+194,304
| +10% | +$919K |
2023 Q4
2 quarters
|
|
|
10
Merck
MRK
$365B
| $10.2M | 2.98% |
+81,508
| New | +$10.5M |
2024 Q2
0 quarters
|
|
|
11
GSK
GSK
$103B
| $9.47M | 2.78% |
+245,933
| New | +$10.3M |
2024 Q2
0 quarters
|
|
12
Autolus Therapeutics
AUTL
$351M
| $9.27M | 2.72% |
2,662,732
-302,989
| -10% | -$1.31M |
2023 Q4
2 quarters
|
|
|
13
Arcutis Biotherapeutics
ARQT
$3.46B
| $8.98M | 2.64% |
965,392
-1,240,507
| -56% | -$11.2M |
2023 Q4
2 quarters
|
|
14
Cabaletta Bio
CABA
$313M
| $8.81M | 2.59% |
1,178,105
+174,189
| +17% | +$2.14M |
2023 Q4
2 quarters
|
|
15
DELISTED
KalVista Pharmaceuticals
KALV
| $8.68M | 2.55% |
736,765
-424,295
| -37% | -$4.95M |
2023 Q4
2 quarters
|
|
16
Biohaven
BHVN
$2.28B
| $8.1M | 2.38% |
233,255
+149,794
| +179% | +$5.92M |
2023 Q4
2 quarters
|
|
17
VistaGen Therapeutics
VTGN
$8.13M
| $5.85M | 1.72% |
1,848,582
| – | – |
2023 Q4
2 quarters
|
|
18
Immatics
IMTX
$977M
| $5.84M | 1.72% |
502,207
+10,281
| +2% | +$116K |
2023 Q4
2 quarters
|
|
19
Denali Therapeutics
DNLI
$3.18B
| $5.83M | 1.71% |
+251,010
| New | +$4.82M |
2024 Q2
0 quarters
|
|
|
20
Insmed
INSM
$26.2B
| $5.83M | 1.71% |
86,980
-185,468
| -68% | -$7.19M |
2023 Q4
2 quarters
|
|
21
Celldex Therapeutics
CLDX
$2.41B
| $5.35M | 1.57% |
+144,467
| New | +$5.45M |
2024 Q2
0 quarters
|
|
22
Larimar Therapeutics
LRMR
$279M
| $5.11M | 1.5% |
704,349
-36,528
| -5% | -$280K |
2023 Q4
2 quarters
|
|
23
TScan Therapeutics
TCRX
$12.6M
| $4.94M | 1.45% |
+845,069
| New | +$6.66M |
2024 Q2
0 quarters
|
|
24
Edgewise Therapeutics
EWTX
$5.09B
| $4.88M | 1.43% |
+271,057
| New | +$4.73M |
2024 Q2
0 quarters
|
|
25
Corbus Pharmaceuticals
CRBP
$76M
| $4.59M | 1.35% |
+101,479
| New | +$4.27M |
2024 Q2
0 quarters
|
|
Similar funds
GFI
CTAF
Stempoint Capital's Q2 2024 Portfolio in Review
As of Q2 2024, Stempoint Capital held 79 positions worth $340M, down 10% from $378M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Stempoint Capital deployed $15.6M of net new capital in Q2 2024, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Immunocore: 339,351 shares worth $11.5M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $11.2M trimmed.
- Stempoint Capital's largest Q2 2024 buy was Immunocore: 339,351 shares worth $11.5M.
- Stempoint Capital added most to Immunovant in Q2 2024, an estimated $10.9M increase.
- Stempoint Capital's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $11.2M.
- Stempoint Capital fully exited Eli Lilly in Q2 2024, selling an estimated $11.7M.
- Stempoint Capital's ten largest holdings make up 55% of its $340M portfolio in Q2 2024.
- Stempoint Capital opened 17 new positions and closed 36 in Q2 2024.
- Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $340M.
Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.